Pipeline

Learn more about Lundbeck's mid- to late-stage development program (phase 1 projects are not included)

Disease

Compound

Phase II

Phase III

Registration Application

Schizophrenia

Lu AF35700

 

   

 

Schizophrenia

Brexpiprazole

 

 

   

PTSD

Brexpiprazole

   

 

 

Alzheimer's disease

Brexpiprazole

  

   

 

Bipolar disease

Brexpiprazole

 

   

 

 

 

Compound

 

Lu AF35700

Lu AF35700 has a novel pharmacological profile with predominant D1 vs. D2 dopamine receptor occupancy, and a high occupancy of 5-HT2A and 5-HT6 serotonin receptors. 

For more information and study locations, please visit www.clinicaltrials.gov.

Brexpiprazole 

Brexpiprazole is a new molecule (i.e., not a metabolite or isomer) discovered by Otsuka and co-developed by Otsuka and Lundbeck. The drug was approved in the US on 10 July, as an adjunctive therapy to antidepressants in adults with major depressive disorder and as a treatment in adults with schizophrenia.

For more information and study locations, please visit www.clinicaltrials.gov.

Patient section

Get a glimpse of a life affected by psychiatric or neurological disorders

 

Read more

Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.